Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow-to-Debt Ratio
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow-to-Debt Ratio of 0.23x as of March 2026, meaning its operating cash flow of $50.20 Million could theoretically repay 0% of its total liabilities ($219.59 Million) in one year. Check Kiniksa Pharmaceuticals Ltd (KNSA) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kiniksa Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Kiniksa Pharmaceuticals Ltd across 10 annual periods. Also explore KNSA total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Kiniksa Pharmaceuticals Ltd (2016–2025)
Year-by-year debt coverage analysis for Kiniksa Pharmaceuticals Ltd. For market capitalisation and broader financial context, see KNSA market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | $25.69 Million | $196.03 Million | ▼ -27.5% |
| 2024 | 0.18x | $25.69 Million | $142.12 Million | ▲ +18.9% |
| 2023 | 0.15x | $13.30 Million | $87.48 Million | ▲ +66.3% |
| 2022 | 0.09x | $5.81 Million | $63.52 Million | ▲ +103.5% |
| 2021 | -2.64x | $-126.30 Million | $47.76 Million | ▲ +27.3% |
| 2020 | -3.64x | $-136.53 Million | $37.53 Million | ▲ +33.1% |
| 2019 | -5.44x | $-158.37 Million | $29.11 Million | ▼ -186.7% |
| 2018 | -1.90x | $-81.01 Million | $42.70 Million | ▼ -418.4% |
| 2017 | -0.37x | $-50.22 Million | $137.20 Million | ▼ -37.6% |
| 2016 | -0.27x | $-21.87 Million | $82.20 Million | — |